EUVIMEDEUVIMED entdecken
Fallbericht

Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism

Peiheng Zhang, Yang Yu, Ying Gao, Geheng Yuan, Junqing Zhang, Wei Wang

Hemodialysis International · 2023

DOI: 10.1111/hdi.13063 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hemodialysis International, 2023. Verfasst von Peiheng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Hypercalcemia, Hyperparathyroidism. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The most appropriate surgical procedure for tertiary hyperparathyroidism is still controversial. Medical management may be considered in those patients with failed previous surgical intervention. There are limited medical options for tertiary hyperparathyroidism with renal dysfunction. The monoclonal antibody denosumab has been used in patients with osteoporosis and hypercalcemia of malignancy. We report a case of medically refractory hypercalcemia caused by tertiary hyperparathyroidism treated with denosumab. A 46‐year‐old female was on hemodialysis for 10 years. She was diagnosed with tertiary hyperparathyroidism due to hypercalcemia with a high level of intact parathyroid hormone (iPTH, 1411 pg/ml). After right parathyroidectomy 6 weeks, her serum calcium remained persistently elevated (Ca, 3.17 mmoL/L). Denosumab (60 mg) was administered subcutaneously, and her serum calcium quickly decreased (from 3.43 to 2.04 mmoL/L within 8 days) and was slightly elevated (Ca, 2.8 mmoL/L) 3 months later. We conclude that denosumab has a significant effect on the reduction of serum calcium for tertiary hyperparathyroidism patients. The long‐term treatment effect and safety warrant more studies in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypercalcemiaHyperparathyroidismFemaleHumansMiddle AgedCalciumRenal DialysisDenosumabParathyroid Hormone

Stichwörter der Autor:innen

denosumabhemodialysishypercalcemiatertiary hyperparathyroidism

Substanzen

CalciumDenosumabParathyroid Hormone

Autor:innen und Institutionen

  • Department of Endocrinology, Peking University First Hospital, Beijing, China.

Zitieren

APA

Zhang, P., Yu, Y., Gao, Y., Yuan, G., Zhang, J., & Wang, W. (2023). Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism. Hemodialysis International. https://doi.org/10.1111/hdi.13063

Vancouver

Zhang P, Yu Y, Gao Y, Yuan G, Zhang J, Wang W. Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism. Hemodialysis International. 2023. doi:10.1111/hdi.13063

BibTeX
@article{Zhang2023,
  author = {Zhang, Peiheng and Yu, Yang and Gao, Ying and Yuan, Geheng and Zhang, Junqing and Wang, Wei},
  title = {Denosumab treatment for refractory hypercalcemia in a hemodialysis patient with tertiary hyperparathyroidism},
  journal = {Hemodialysis International},
  year = {2023},
  doi = {10.1111/hdi.13063}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche